- Previous Close
0.0099 - Open
0.0090 - Bid 0.0093 x --
- Ask 0.0097 x --
- Day's Range
0.0090 - 0.0090 - 52 Week Range
0.0060 - 0.0200 - Volume
50,000 - Avg. Volume
584,772 - Market Cap (intraday)
1.02M - Beta (5Y Monthly) -0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
www.evofem.comRecent News: EVFM
View More
Performance Overview: EVFM
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVFM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVFM
View MoreValuation Measures
Market Cap
1.05M
Enterprise Value
47.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.04
Price/Book (mrq)
--
Enterprise Value/Revenue
2.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-45.76%
Return on Assets (ttm)
-27.94%
Return on Equity (ttm)
--
Revenue (ttm)
19.36M
Net Income Avi to Common (ttm)
-8.96M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
127k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.88M